Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Assets Average (2023 - 2026)

Compass Therapeutics' Assets Average history spans 4 years, with the latest figure at $212.4 million for Q1 2026.

  • On a quarterly basis, Assets Average rose 56.24% to $212.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $212.4 million, a 56.24% increase, with the full-year FY2025 number at $180.0 million, up 21.1% from a year prior.
  • Assets Average hit $212.4 million in Q1 2026 for Compass Therapeutics, down from $225.4 million in the prior quarter.
  • Over the last five years, Assets Average for CMPX hit a ceiling of $225.4 million in Q4 2025 and a floor of $124.1 million in Q2 2025.
  • Historically, Assets Average has averaged $169.4 million across 4 years, with a median of $163.5 million in 2023.
  • Biggest five-year swings in Assets Average: fell 21.66% in 2025 and later surged 56.24% in 2026.
  • Tracing CMPX's Assets Average over 4 years: stood at $163.5 million in 2023, then fell by 11.43% to $144.8 million in 2024, then surged by 55.7% to $225.4 million in 2025, then fell by 5.79% to $212.4 million in 2026.
  • Business Quant data shows Assets Average for CMPX at $212.4 million in Q1 2026, $225.4 million in Q4 2025, and $174.0 million in Q3 2025.